Considering the clinical relevance of deficits in NRG1 and DISC1 gene function in neurodegenerative and neuropsychiatric disorders (such as schizophrenia, Parkinson’s disease, and Alzheimer’s disease), our findings could be considered proof-of-concept for a new treatment strategy of these diseases. This evidence concerns the gene NRG1 and early-onset autosomal dominant Alzheimer disease.